Cargando…
Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
INTRODUCTION: Evidence of a direct comparison between dipeptidyl-peptidase 4 inhibitors (DPP-4is) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remains lacking, and no clear treatment strategy or rationale has been established using these drugs. This study aimed to compare the overall effi...
Autores principales: | Sugawara, Masahiro, Fukuda, Masahiro, Sakuma, Ichiro, Wakasa, Yutaka, Funayama, Hideaki, Kondo, Akira, Itabashi, Naoki, Maruyama, Yasuyuki, Kamiyama, Takashi, Utsunomiya, Yasunori, Yamauchi, Akira, Yoshii, Hidenori, Yamada, Hirokazu, Mochizuki, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363101/ https://www.ncbi.nlm.nih.gov/pubmed/37410308 http://dx.doi.org/10.1007/s13300-023-01438-w |
Ejemplares similares
-
Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022) -
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022) -
Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
por: Sasaki, Takashi, et al.
Publicado: (2018) -
Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
por: Araki, Shin‐ichi
Publicado: (2019) -
Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice
por: Nishina, Sohji, et al.
Publicado: (2018)